·Ñ³ÇȾɫÌå,Philadelphia chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔµ¥ºËϸ°û°×Ѫ²¡,acute monocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ATM»ùÒò,ATM geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
COX»Ø¹éÄ£ÐÍ,COX regression modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Smac»ùÒò,Smac GeneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆÏÌÑÌÇÉñ¾õ£°·ºÏ³Éø,glucosylceramide synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ki67»ùÒò,Ki67 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸Æµ÷ËØÞ׿¹¼Á,Calmodulin antagonistÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃÖÂþ´óBϸ°ûÁܰÍÁö,diffuse large B-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¸È鶯ÎïÀ×ÅÁÃ¹ËØ°Ðµ°°×,mammalian target of rapamycinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔ·ÇÁܰÍϸ°û°×Ѫ²¡,acute non-lymphocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒ߹̶¨µçÓ¾,Immunofixation electrophoresisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô°©»ùÒòµ°°×ÖÊc-myc,proto-oncogene proteins c-mycÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¤ÆÚÉú´æ,Long-term survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏÔÏñ¼Á,imaging agentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
FAB·ÖÐÍ,FAB classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì×ϸ°ûÁܰÍÁö,Mantle cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
As_2O_3,arsenic trioxideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ç»ôÆæ½ð/Ò©ÎïÁÆ·¨,non-Hodgkin/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HL-60ϸ°ûϵ,HL-60 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Tϸ°ûÁܰÍÁö,T-cell lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NB4ϸ°ûÖê,NB4 cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
WesternÓ¡¼£·¨,Western blottingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÜÆÚµ°°×E,cyclin EÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áò»¯Éé,Arsenic SulfideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÎ̬²ÎÊý,morphological parametersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂýÐÔ°×Ѫ²¡,chronic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
1ºÅȾɫÌå,Chromosome 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂýÐÔËèÐÔ°×Ѫ²¡,chronic myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ¥Åä¸ÅÂÊ,matching probabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
³¬Î¢Èõ·¢¹â,Ultraweak luminescenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
U266ϸ°û,U266 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢С²ÐÁô²¡Ôî,minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×éÖ¯Òò×Ó;¾¶ÒÖÖÆÎï-2,tissue factor pathway inhibitor-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ëèϵ°×Ѫ²¡,myeloid leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BurkittÁܰÍÁö,Burkitt lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö×ÓÏÔÏñ,Molecular imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
L5178Yϸ°û,L5178Y cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȾɫÌåÏÔ´ø,chromosome bandingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°ëë×°±ËáÄÚëÄøÀà,Cysteine endopeptidasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×é֯ѧÀàÐÍ,histological typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍÁöϸ°û,Lymphoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ùͯ°×Ѫ²¡,Childhood leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËèÁöϸ°û,myeloma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÎÞ²¡Éú´æ,disease-free survivalÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûоƬ,cell microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍÁöÑùÈâÑ¿Öײ¡,lymphomatoid granulomatosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢Á¿²ÐÁô²¡,Minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔìѪϸ°ûÉú³¤Òò×Ó,Hematopoietic cell growth factorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NKϸ°ûÊÜÌå,NK cell receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
MIC·ÖÐÍ,MIC classificationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐÔÔçÓ×Á£Ï¸°ûÐÔ°×Ѫ²¡,acute promyelocytic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ä±äÐÔÁܰÍÁö¼¤Ã¸,anaplastic lymphoma kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
K562/ADMϸ°û,K562/ADM cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BCR/ABL»ùÒò,BCR/ABL geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ÔÌåÍâÖÜѪÔìѪ¸Éϸ°ûÒÆÖ²,autologous peripheral blood stem cell transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÖÆÚϵͳ,staging systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃâÒßÇòµ°°×ÖØÁ´,immunoglobulin heavy chainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢С²ÐÁô²¡±ä,minimal residual diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PhȾɫÌå,Ph chromosomeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö×ÓÑÇÐÍ,molecular subtypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BP1»ùÒò,BP1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂãÊóÄ£ÐÍ,Nude mice modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇËè¼äÖÊϸ°û,bone marrow stromal cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
8ºÅȾɫÌå,Chromosome 8Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç»¯Ñ§DNAÉúÎï´«¸ÐÆ÷,electrochemical DNA biosensorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á£Ï¸°ûÈâÁö,Granulocytic sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Livinµ°°×,Livin proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µªÀ¶ËÄßò,nitroblue tetrazoliumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¡ÀíÑ§ÌØÕ÷,pathological featureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
P53ͨ·,P53 pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×Ѫ²¡Ï¸°ûϵ,leukemic cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Òì»ùÒòÍâÖÜѪÔìѪ¸Éϸ°ûÒÆÖ²,Allogeneic peripheral blood stem cell transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ¢ÔàÖ×Áö,splenic neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
K562/ADMϸ°ûÖê,K562/ADM cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ð¤Ä¤Ïà¹ØÁܰÍÑù×éÖ¯,Mucosa-associated lymphoid tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËIL-24,Human IL-24Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ôÆæ½ð²¡,Hodgkin diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ùͯ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡,childhood acute lymphoblastic leukemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Rad51»ùÒò,Rad51 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼äÆÚÓ«¹âÔλÔÓ½»,interphase fluorescence in situ hybridizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
AML1/ETOÈںϻùÒò,AML1/ETO fusion geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
bcl-6»ùÒò,bcl-6 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éé¼Á/ÖÎÁÆÓ¦ÓÃ,arsenicals/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·´Òå¹ÑºËÜÕËáÀà,antisense oligonucleotidesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Bcl-2»ùÒò¼Ò×å,Bcl-2 gene familyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
tkλµã,tk geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Òì»ùÒòÒÆÖ²,Allogeneic transplantationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
B7»ùÒò,B7 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Bimµ°°×,Bim proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
VAD·½°¸,VAD regimenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²®»ùÌØÁܰÍÁö,Burkitt lymphomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û±íÃæ¿¹Ô,cell surface antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö»µËÀÒò×ÓÏà¹ØµÄµòÍöÓÕµ¼ÅäÌå,TRAILÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ZO-1»ùÒò,ZO-1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ó¡½äϸ°û°©,Signet-ring cell carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
BCRP»ùÒò,BCRP geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ùͯÐÄÀí,Children PsychologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CEMϸ°û,CEM cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ãÎ÷µØÇø,Guangxi regionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|